Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.
The volume of practice-changing CAR T-cell therapy abstracts presented at ASH Annual Meeting and Exposition in December, however, illustrate the modality’s critical role in the blood cancer treatment armamentarium, according to Ryan D. Cassaday, MD, associate professor at University of Washington and Fred Hutchinson Cancer Center and member of the Healio | Cell Therapy Next Peer Perspective Board.
